Search

Jun 10, 2024
Longboard Pharma's CEO describes today's open label extension data for bexicaserin in Developmental and Epileptic Encephalopathies
Kevin Lind explains how patients randomized to therapy and placebo crossover patients are seeing comparable reductions in seizure levels....